Clear Creek Financial Management LLC Takes $1.17 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Clear Creek Financial Management LLC acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 12,702 shares of the biopharmaceutical company's stock, valued at approximately $1,173,000.

Several other institutional investors have also added to or reduced their stakes in GILD. Caprock Group LLC raised its holdings in shares of Gilead Sciences by 10.3% during the fourth quarter. Caprock Group LLC now owns 42,369 shares of the biopharmaceutical company's stock valued at $3,914,000 after purchasing an additional 3,970 shares during the last quarter. AA Financial Advisors LLC grew its holdings in shares of Gilead Sciences by 50.7% in the fourth quarter. AA Financial Advisors LLC now owns 3,842 shares of the biopharmaceutical company's stock worth $355,000 after acquiring an additional 1,293 shares during the period. Crews Bank & Trust purchased a new position in Gilead Sciences in the fourth quarter worth about $31,000. OLD National Bancorp IN boosted its stake in shares of Gilead Sciences by 5.2% during the 4th quarter. OLD National Bancorp IN now owns 17,395 shares of the biopharmaceutical company's stock worth $1,607,000 after acquiring an additional 857 shares during the last quarter. Finally, DMC Group LLC boosted its holdings in shares of Gilead Sciences by 2.5% during the 4th quarter. DMC Group LLC now owns 14,513 shares of the biopharmaceutical company's stock valued at $1,341,000 after purchasing an additional 358 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

GILD has been the subject of several recent research reports. Wolfe Research started coverage on Gilead Sciences in a research report on Friday, November 15th. They issued an "outperform" rating and a $110.00 price target for the company. Mizuho increased their price objective on shares of Gilead Sciences from $90.00 to $100.00 and gave the stock an "outperform" rating in a research report on Thursday, November 21st. JPMorgan Chase & Co. boosted their target price on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an "overweight" rating in a research note on Wednesday, January 29th. Leerink Partners upgraded Gilead Sciences from a "market perform" rating to an "outperform" rating and raised their price objective for the stock from $74.00 to $96.00 in a report on Monday, October 21st. Finally, Leerink Partnrs upgraded shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a report on Monday, October 21st. Eleven equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $98.39.

Gilead Sciences Price Performance

GILD stock traded up $2.37 during midday trading on Wednesday, reaching $100.36. The stock had a trading volume of 4,176,482 shares, compared to its average volume of 6,847,283. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $100.40. The company has a market cap of $125.08 billion, a price-to-earnings ratio of 1,114.37, a price-to-earnings-growth ratio of 1.37 and a beta of 0.18. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The company's fifty day simple moving average is $92.71 and its 200 day simple moving average is $86.32.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.58 by $0.44. The business had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business's revenue was up 7.0% compared to the same quarter last year. During the same period in the prior year, the business earned $2.29 earnings per share. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post 4.34 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Jeffrey Bluestone sold 6,788 shares of the business's stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the sale, the director now owns 8,920 shares of the company's stock, valued at $815,198.80. The trade was a 43.21 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 248,645 shares of the stock in a transaction on Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the sale, the chief financial officer now owns 138,919 shares in the company, valued at approximately $12,886,126.44. This trade represents a 64.16 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 572,824 shares of company stock worth $53,611,715. Insiders own 0.29% of the company's stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.